

#13/I.D.S.

PTO/SB/08A (08-00)

Approved for use through 4/30/2003. OMB 0651-

0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF


COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/918,026
				Filing Date	July 30, 2001
				First Named Inventor	Rosanne M. Crooke
				Group Art Unit	1635
				Examiner Name	Gibbs, Terra C.
Sheet	1	of	2	Attorney Docket Number	ISPH-0588

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
					RECEIVED
					APR 11 2003
					TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -	Number ⁴ -	Kind Code ⁵ (if known)				
	AD	JP	06172186	A	12-04-1992	Toyoma Chem Co LTD.		
			*See Abstract BQ					

Examiner Signature		Date Considered	9/4/03
--------------------	---	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See

Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/918,026
				Filing Date	July 30, 2001
				First Named Inventor	Rosanne M. Crooke
				Group Art Unit	1635
				Examiner Name	Gibbs, Terra C.
Sheet	2	of	2	Attorney Docket Number	ISPH-0588

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column issue number(s), publisher, city and/or country where published	T ²	
PS	BP	BUHMAN, Resistance to Diet-Induced Hypercholesterolemia and Gallstone Formation in ACAT2-Deficient Mice, Nature Medicine, Vol 6, No. 12 (December 2000)		
	BQ	Abstract of JP 06172186 A, (Toyama Chem CO LTD.) (December 4, 1992)		
PS	BR	BRAASCH, Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression, Biochemistry, Vol. 41, No. 14, pg. 4504-4510 (April 9, 2002)		
	BS	AGRAWAL, Antisense Oligonucleotides: Towards Clinical Trials, TibTech, Vol. 14, pg. 376-387, (October 1996)		
	BT	TAMM, Antisense Therapy in Oncology: New Hope for an Old Idea?, The Lancet, Vol. 358, pg. 489-497, (August 11, 2001)		
	BU	GEWIRTZ, Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on its Promise, Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 3161-3163, (April 1996)		
	BV	BRANCH, A Good Antisense Molecule is Hard to Find, TIBS 23, pp. 4549, (February 1998)		
PS	BW	TAYLOR, Antisense Oligonucleotides: A Systematic High-Throughput Approach to Target Validation and Gene Function Determination, DDT, Vol. 4, No. 12 (December 1999)		

RECEIVED

APR 11 2003

TECH CENTER 1600/2000

Examiner Signature	<i>Luna SGL</i>	Date Considered	9/4/03
--------------------	-----------------	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.